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Membrane destabilizationHuman-β-defensins HBD-1–3 are important components of the innate immune system. Synthetic peptides
Phd-1–3 with a single disulphide bond, spanning the cationic C-terminal region of HBD-1–3, have antimicrobial
activity. The interaction of Phd-1–3 with model membranes was investigated using isothermal titration
calorimetry (ITC) and steady-state ﬂuorescence polarization to understand the biophysical basis for the mecha-
nism of antimicrobial action. Calorimetric titration of POPE:POPG (7:3) vesicles with peptides at 25 °C and 37 °C
showed complex proﬁles with two distinct regions of heat changes. The data indicate binding of Phd-1–3 at
37 °C to both negative and zwitterionic lipid vesicles is exothermic with low enthalpy values (ΔH~−1.3 to
−2.8 kcal/mol) as compared to amphipathic helical antibacterial peptides. The adsorption of peptides to
negatively charged lipid membranes is modulated by electrostatic interactions that are described by surface
partition equilibrium model using Gouy–Chapman theory. However, this model could not explain the isotherms
of peptide binding to zwitterionic lipid vesicles. Fluorescence polarization of TMA-DPH (1-[4-(trimethylammonio)
phenyl]-6-phenyl-1,3,5-hexatriene) and DPH (1,6-diphenyl-1,3,5-hexatriene) located in the head group and acyl
chain region respectively, indicates that the peptides interact with interfacial region of negatively charged
membranes. Based on the results obtained, we conclude that adsorption of cationic peptides Phd-1–3 on lipid
surface do not result in conformational change or pore formation. It is proposed that interaction of Phd-1–3
with the negatively charged lipid head group causes membrane destabilization, which in turn affects the
efﬁcient functioning of cytoplasmic membrane proteins in bacteria, resulting in cell death.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The antimicrobial peptides β-defensins are important components
of the innate immune system of humans and other mammals. They
are 30–50 residue long peptides showing antimicrobial activity
against bacteria, fungi and enveloped viruses [1–7]. The primary
structures of human-β-defensins HBD-1–4 indicate that there are
considerable variations in the distribution of anionic and cationic
residues. The conserved motif of six cysteines in β-defensins aid in
generating a three-dimensional fold consisting of three antiparallel
β-strands with a short stretch ofα-helix in the amino-terminal region
[8–12]. Despite the almost identical three-dimensional structures, the
antibacterial spectra of human-β-defensins vary. HBD-1 and 2 are ac-
tive predominantly against Gram-negative bacteria as compared to
Gram-positive bacteria [13–15], while HBD-3 exhibits activity against
both Gram-negative and Gram-positive bacteria. Physiological con-
centration of NaCl attenuates the activities of HBD-1 and HBD-2 but+91 40 27160591.
mari).
l rights reserved.not HBD-3 [13,14,16,17]. Nuclear magnetic resonance (NMR) spec-
troscopy, dynamic and static light scattering data of HBD-1–3
indicated that HBD-3 was a dimer, while HBD-1 and HBD-2 were mo-
nomeric in solution [12]. The structural data derived from NMR spec-
troscopy also revealed that the surface charge density of each of the
defensins is markedly different, which may result in varying activities
of these defensins [12]. While the exact mechanism of antibacterial
activity is yet to be established unequivocally, there are evidences
to suggest that human-β-defensins exert their antibacterial effects
by membrane disruption, inducing permeabilization of target cell
membranes [5,6,9,10,18,19]. Extensive investigations have been
carried out on native defensins as well as designed analogs to under-
stand the role of the conserved three-dimensional structure on their
antimicrobial activity. These studies have indicated that the native
disulphide arrangement is not essential for antibacterial activity.
Truncated analogs, particularly peptides corresponding to C-terminal
segments, exhibited antimicrobial activity [10,18,20–29]. Peptide–
membrane interaction studies on HBD-3 and its analogs have indicat-
ed that peptide charge density, is an important parameter for antimi-
crobial activity, while the overall hydrophobicity correlates with
cytotoxicity to mammalian cells [21,28,30,31].
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nique, which provides a qualitative and thermodynamic description
of peptide binding to lipids using unsupported bilayers. The heat
ﬂow resulting from the binding of the peptide to lipid vesicles gives
information about peptide structure and function in the membrane
[32]. This technique has been used to study the interaction of several
antimicrobial peptides such as gramicidin S, indolicidin, magainin,
and PGLa with lipids and to determine their mechanisms of action
[33–37]. Such detailed studies with β-defensins have not been inves-
tigated. However, ITC studies of Def-A, a mutant of HBD-3 with lipid
vesicles showed their preferential interaction with negatively
charged membranes compared to zwitterionic membranes [38]. Dif-
ferential scanning calorimetry (DSC) experiments with HNP-2 also
showed similar results [39].
We have shown that the C-terminal analogs of human-β-defensins
HBD-1–3: Phd-1: ACPIFTKIQGTYRGKAKCK, Phd-2: FCPRRYKQIGTG
LPGTKCK and Phd-3: SCLPKEEQIGKSTRGRKCRRKK, in which the cyste-
ines are connected by a disulﬁde bond, exhibit antimicrobial activities,
that is attenuated in the presence of NaCl [18,22]. Interaction of the pep-
tides with lipid monolayers demonstrates their afﬁnity and greater ex-
tent of penetration into negatively charged lipids as compared to
zwitterionic lipids. Their effective insertion into monolayers correlated
with their ability to permeabilize the inner membrane of Escherichia
coli [40]. In this paper, the interaction of Phd-1–3 with model
membranes investigated by ITC and steady-state ﬂuorescence polariza-
tion measurements is described.
2. Materials and methods
2.1. Materials
POPC, 1-palmitoyl-2-oleoyl-sn-glycerophospho-choline; POPE, 1-
palmitoyl-2-oleoyl-sn-glycerophosphoglycerol and POPG, 1-palmitoyl-
2-oleoyl-sn-glycerophosphoglycerol were purchased from Avanti Polar
Lipids (Alabaster). Cholesterol was obtained from Sigma. 1,6-Diphenyl-
1,3,5-hexatriene (DPH) and 1-[4-(trimethylammonio)phenyl]-6-
phenyl-1,3,5-hexatriene (TMA-DPH), 3,3′-dipropylthiocarbo-cyanine
iodide [diS-C3-(5)] were from Molecular Probes (Eugene, OR). All
other chemicals were of the highest grade available. The synthesis of
peptides Phd-1–3 has been described earlier [18].
2.2. Preparation of large unilamellar vesicles (LUVs)
The lipid vesicles were prepared as follows: 20 mM POPE:POPG
(7:3) or POPC:Cholesterol (7:3) lipids were dried under vacuum
overnight. The lipid ﬁlm thus obtained was hydrated with 1 ml of
5 mM HEPES buffer, pH 7.4 and the solution was subjected to vortex
mixing. The multilamellar vesicles obtained were extruded through
a small volume extrusion apparatus [41] (Avestin Inc., Ottawa, ON)
equipped with a polycarbonate membrane ﬁlter (19 mm diameter,
200 nm pore diameter) 40 times to produce LUVs with vesicle size
of 200 nm. The size distribution of vesicles was conﬁrmed by dynamic
light scattering (DLS) measurements.
2.3. High-sensitivity isothermal titration calorimetry (ITC)
Isothermal titration calorimetry was performed on a VP instru-
ment (MicroCal, MA) at different temperatures (25 °C or 37 °C) with
a reaction cell volume of 1.39 ml. Solutions were degassed under
low pressure before use to avoid the formation of air bubbles while
titrating. The peptide solution (50 μM) in 5 mM HEPES buffer,
pH 7.4 was placed in the calorimeter cell and lipid vesicles (20 mM)
injected via 300 μl titration syringe in aliquots of 3 μl at regular time
intervals of 300 s to allow the solution to reach equilibrium. The cell
was stirred continuously at 300 rpm. The calorimeter was calibrated
electrically. The resulting heat changes after injection of vesiclesinto the sample cell were recorded as a function of time. The heats
of dilution (hdil) were determined in control experiments by injecting
lipid vesicles into buffer and were subtracted from the heat of reac-
tion (h) determined in the corresponding peptide–lipid binding
experiments to calculate actual heat of reaction (δh=h−hdil). The
heat of reaction was obtained by integrating the area under each
peak of heat ﬂow tracings. The data were acquired by using computer
software developed by MicroCal LLC.
2.3.1. Measurements of binding isotherms from high sensitivity titration
calorimetry
Binding isotherms of Phd-1–3 to POPE:POPG (7:3) or POPC:
Cholesterol (7:3) at 37 °C were determined by injecting lipid
vesicles into peptide solutions [32,37]. The LUVs injected into the
peptide solution produce heat of reaction denoted as δh. δhi is the
experimentally measured heat of reaction at the ith injection andPi
1
δhi is the cumulative heat of reaction after i injections, so that the
total heat of reaction after last i.e. the n injections is
Pn
1
δhi. The
molar heat of reaction or enthalpy is calculated using the formula
[32,37]
ΔH ¼
Xn
1
δhi=CpVcell ð1Þ
where Cp is the concentration of the peptide and Vcell is the volume of
the reaction cell in the calorimeter. The amount of bound peptide to
the lipid membranes after i injections is given by
X ið Þp ¼ n ið Þp =np ¼
Xi
1
δhi=
Xn
1
δhi ð2Þ
where np(i) is the molar amount of bound peptide after the i injections
and np is the total amount of peptide in the calorimeter cell.
The equilibrium concentration of free peptide in the calorimeter cell,
Cf, (i) at each point of titration can be calculated as
C ið Þf ¼ Cο 1−X
ið Þ
p
 
ð3Þ
where, Co is the total peptide concentration. The lipid concentration in
the calorimeter cell increases in discrete steps during the course of
titration. After i injections the molar amount of lipid, nL(i) is given by
n ið ÞL ¼ i:Vinj:CL ð4Þ
where, CL is the lipid concentration of stock solution and Vinj is injected
volume per titration step i. Only the lipids in the outer layer of LUVs
(50% of the total lipid) were considered for the calculation. So the
extent of binding Xb is calculated as molar ratio of bound peptide to
injected lipid. The plot Xb versus Cf gives binding isotherm.
X ið Þb ¼ n
ið Þ
p =n
ið Þ
L ð5Þ
Xb ¼ Kb Cf
 
ð6Þ
where Kb denotes apparent binding constant and Kb(Cf) describes
functional dependence of Xb on Cf .
2.3.2. Analysis of binding isotherm by Gouy–Chapman theory
The surface partition equilibrium model has been used for ther-
modynamic analysis of binding of Phd-1–3 to POPE:POPG (7:3)
vesicles at 37 °C, where electrostatic and hydrophobic contributions
to the membrane afﬁnity of the peptides are dealt with separately.
This model has been based on Gouy–Chapman theory [32,42–44]
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several cationic peptides [35,37,44–46]. The speciﬁc condition applied
in this model is that the peptide adsorption is linearly related to
the peptide concentration immediately above the membrane surface
CM and not to the equilibrium concentration of free peptide Cf ,
Xb ¼ KCM ð7Þ
K, the apparent surface partition coefﬁcient describes the hydro-
phobic binding or adsorption process that is independent of the pep-
tide concentration. The relationship between CM and Cf is given by the
Boltzmann equation, accounting for electrostatic interactions,
CM ¼ Cf exp− ZpFοΨοð Þ=RT ð8Þ
Thus, peptide surface concentration CM depends on the equilibri-
um concentration of free peptide Cf, effective peptide charge Zp and
membrane surface potential ψ0, which can be approximated by
means of the Gouy–Chapman theory. RT is the thermal energy and
F0 Faraday constant. Surface potential (ψ0) in the absence of peptide
is taken as −115 mV [47,48]. Theoretical solutions are found for
Eqs. (7) and (8) by systematically varying K, effective peptide charge
Zp and surface potential (ψ0).
2.4. Fluorescence polarization measurements
Fluorescence polarization measurements were performed on
Fluorolog FL3-22 ﬂuorescence spectrophotometer (Horiba Jobin
Yvon, NJ) with excitation wavelength at 365 nm and the emission
wavelength at 425 nm. Excitation slit width of 2 nm and emission
slit width of 5 nm were used for all the measurements. Two ﬂuores-
cent probes, DPH dissolved in tetrahydrofuran and TMA-DPH dis-
solved in methanol were used in the ﬂuorescence polarization
measurements. All experiments were done at room temperature
using LUVs of 200 nm diameter of either (90 μM) POPE:POPG (7:3)
or (180 μM) POPC:Cholesterol (7:3) in 5 mM HEPES buffer, pH 7.4.
DPH/TMA-DPH was added into the liposomes at 1 mol%. Fluorescence
was measured at regular intervals of 30 s between successive open-
ings of the excitation shutter to reverse any photoisomerization ofFig. 1. Titration calorimetry of peptides Phd-1–3 with POPE:POPG (7:3) LUVs at 37 °C. Peptide
vesicles (20 mM) suspended in the same buffer. Each peak corresponds to injection of 3 μl lipid
cumulative heat of reaction,
Pi
1
δhi calculated from the area underneath the titration peaks, asDPH and TMA-DPH. Polarization values were calculated from the
equation
P ¼ IVV−GIVH=IVV þ GIVH
where, IVV and IVH are the measured ﬂuorescence intensities (after
appropriate background subtraction) with the excitation polarizer
vertically oriented and emission polarizer vertically and horizontally
oriented, respectively. G is the grating correction factor, and is equal
to IHV/IHH. It is included to correct for the wavelength response to
polarization of the emission optics and detectors [49].
2.5. Permeabilization of lipid vesicles
The ability of peptides to permeabilize POPE:POPG (7:3) model
membranes were examined by monitoring the dissipation of diffu-
sion potential set up in lipid vesicles by valinomycin [23,50]. The cy-
anine dye diS-C3-(5) [23,50] was used in these experiments. Lipid
vesicles with entrapped K+ were diluted into 5 mM HEPES buffer,
pH 7.4, followed by addition of cyanine dye, valinomycin, and pep-
tides. The excitation and emission wavelengths were 620 and
670 nm, respectively. The percentage of ﬂuorescence F recovery was
calculated by using the equation
F ¼ Ft−F0
Ff−F0
" #
 100
where Ft is the ﬂuorescence observed after addition of peptide at time
t, F0 is the ﬂuorescence after addition of valinomycin, and Ff is the
total ﬂuorescence prior to the addition of valinomycin.
3. Results
3.1. Isothermal titration calorimetry and analysis of binding isotherms
Isothermal titrations of LUVs composed of 20 mM POPE:POPG
(7:3) with peptide solutions were carried out at both 25 °C and
37 °C. The titration proﬁles of Phd-1–3 binding to POPE:POPG (7:3)
at 37 °C are shown in Fig. 1(A–C). From these proﬁles, it is evident
that each injection produces an exothermic heat of reaction due to(50 μM) dissolved in 5 mMHEPES buffer pH 7.4 was titrated with POPE:POPG (7:3) lipid
vesicles into calorimeter cell. The lower curve in each case represents the corresponding
a function of the number of injections. (A, D) Phd-1, (B, E) Phd-2 and (C, F) Phd-3.
Fig. 2. Titration calorimetry of peptides Phd-1–3 with POPE:POPG (7:3) LUVs at 25 °C.
Peptide (50 μM) dissolved in 5 mM HEPES buffer pH 7.4 was titrated with POPE:POPG
(7:3) lipid vesicles (20 mM) suspended in the same buffer. Each peak corresponds to
injection of 3 μl lipid vesicles into calorimeter cell. (A) Phd-1, (B) Phd-2 and (C) Phd-3.
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of lipids, as the free peptide concentration in the reaction cell
progressively decreases. The exothermic binding reaction essentially
ceases after four to seven injections. The titration proﬁle can be
divided into two distinct regions. For the ﬁrst few injections, the
exothermic heat of reaction decreases monotonously. After a certain
number of injections, the proﬁle shows a small increase in
magnitude of exothermic heat with each injection for all the three
peptides. The variation of cumulative heat of reaction, with the
number of injections for Phd-1–3 at 37 °C, used to calculate molar
reaction enthalpy ΔH and peptide binding isotherms is shown in
Fig. 1(D–F). The enthalpy values calculated according to Eq. (1) as
described in Section 2.3.1 for binding of Phd-1–3 to POPE:POPG
(7:3) vesicles, are summarized in Table 1. The integrity of lipid
vesicles exposed to the peptides was checked by DLS measurements
at lipid–peptide ratios of 1:1, which corresponds to the ﬁrst addition
of lipid to peptide showing maximum exothermic heat of reaction by
ITC. No signiﬁcant variation in hydrodynamic radii of lipid vesicles
was observed indicating absence of peptide induced disruption or
aggregation of vesicles (data not shown).
The titration proﬁles of Phd-1–3 binding to POPE:POPG (7:3) LUVs
at 25 °C are shown in Fig. 2(A–C). Fig. 2A indicates an initial
exothermic heat of reaction and subsequent endothermic heat of
reaction for binding of Phd-1. However, for Phd-2 and Phd-3 an exo-
thermic heat of reaction is produced due to peptide partitioning
which showed an inﬂection point indicating that heat of reaction no
longer decreased smoothly with each injection (Fig. 2B and C). Thus
two distinct heat change regions were obtained for all the three pep-
tides at both temperatures 25 °C and 37 °C.
The isothermal titration experiments with LUVs composed of both
20 mM POPC:Cholesterol (7:3) and POPC with peptides were carried
out at 37 °C. The titration proﬁles for interaction of peptides with
POPC:Cholesterol (7:3) are shown in Fig. 3. The titration proﬁles
shown in Fig. 3(A–C) indicate that the concentration of free peptide
is reduced with each lipid injection and the exothermic heat of
reaction decreases and drops close to zero. Fig. 3(D–F) shows the
cumulative heat of reaction as a function of lipid injection steps. The
enthalpy values, calculated according to Eq. (1) as described in
Section 2.3.1, are Phd-1 (−0.83 kcal/mol), Phd-2 (−2.48 kcal/mol)
and Phd-3 (−1.86 kcal/mol). The data indicate binding of Phd-1–3
to negatively charged POPE:POPG (7:3) vesicles are slightly more
exothermic as compared to POPC:Cholesterol (7:3) vesicles. The
titration proﬁles for interaction of peptides with POPC are shown in
Fig. S1 (Supplementary data). The traces indicate that peptides do
not bind to POPC vesicles.
The binding isotherms measured for negatively charged lipid ves-
icles POPE:POPG (7:3) at 37 °C according to Eqs. (2)–(6) described in
Section 2.3.1, are shown in Fig. 4(A–C). The Phd-1–3 binding
isotherms were calculated for the ﬁrst phase of heat changes, since
continuous decrease in the magnitude of the exothermic heat of
reaction and maximum heat changes were obtained with increasingTable 1
Thermodynamic parameters for binding of peptides Phd-1–3 to POPE:POPG (7:3)
vesicles at 37 °C.
Peptide Za
Charge
ZP
b
Effective charge
ΔH
kcal/mol
ΔS
cal
TΔS ΔG
kcal/mol
K
[M]−1
Phd-1 +5 +1.8 −1.34 8.22 2.55 −3.89 10
Phd-2 +5 +1.5 −2.80 4.89 1.52 −4.32 20
Phd-3 +7 +1.5 −2.00 7.42 2.30 −4.32 20
aPeptide charge; bEffective charge of peptide; ΔH heat of reaction calculated from
titration experiments according to Eq. (1) described in Section 2.3.1; K was derived
from binding isotherms described in Section 2.3.2. ΔG was calculated according to
the equation ΔG=−RT ln [(55.5M) K]; TΔS was calculated from the formula
ΔG=ΔH−TΔS.injection number as the free peptide concentration decreased
progressively. The data shows a nonlinear dependence of Xb on
equilibrium concentration of free peptide Cf. The value of apparent
binding constant Kb=Xb /Cf is not constant but varies with peptide
concentration. The binding isotherms were analyzed in terms of
the surface partition equilibrium model [44] using Gouy–Chapman
equation as described in Section 2.3.2. Using this model, the
isotherms for a range of peptide effective charge Zp and membrane
surface potential ψ0 were simulated for a given Cf and Xb that
correspond to the best ﬁt to the experimental data. The theoretical
predications (solid line) which coincided with experimental results
(scatter symbols) is shown in Fig. 4(A–C) The membrane surface
concentration CM calculated according to Eqs. (7) and (8) plotted
against the extent of bound peptide to lipid Xb, is shown in Fig. 5(A–C).
Good agreement with experimental data was found when peptide
effective charge Zp is between (+1.5 and +1.8) for peptides Phd-1–3
and (K=10M−1 for Phd-1, K=20 M−1for Phd-2, 3). A linear relation-
ship between Xb to peptide surface concentration, CM is obtained. The
apparent surface partition coefﬁcient K calculated is used to ﬁnd stan-
dard free energy of binding ΔG, using the relation
ΔG ¼−RT ln 55:5Mð ÞK½ 
Fig. 3. Titration calorimetry of peptides Phd-1–3 with POPC: Cholesterol (7:3) LUVs at 37 °C. Peptide (50 μM) dissolved in 5 mM HEPES buffer pH 7.4 titrated with POPC:Cholesterol (7:3)
lipid vesicles (20 mM) suspended in the same buffer. Each peak corresponds to injection of 3 μl lipid vesicles into calorimeter cell. The lower curve in each case represents the corresponding
cumulative heat of reaction,
Pi
1
δhi calculated from the area underneath the titration peaks, as a function of the number of injections. (A, D) Phd-1, (B, E) Phd-2 and (C, F) Phd-3.
Fig. 4. Binding isotherms for binding of Phd-1–3 to POPE:POPG (7:3) LUVs at 37 °C. Extent
of peptide binding to lipid vesicles Xb plotted as a function of equilibrium concentration of
free peptide Cf. (A) Phd-1, (B) Phd-2 and (C) Phd-3. The solid lines correspond to the the-
oretical binding isotherms calculated by combining surface partition equilibriumwith the
Gouy–Chapman theory. The binding constants used for calculations are given in Table 1.
Fig. 5. Binding isotherms for binding of Phd-1–3 to POPE:POPG (7:3) LUVs at 37 °C.
Extent of peptide binding to lipid vesicles Xb plotted as a function of peptide surface
concentration CM. (A) Phd-1, (B) Phd-2 and (C) Phd-3. A linear relationship between
Xb to CM is obtained. The symbols represent the experimental results depicted in Fig. 1.
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for the cratic contribution. The thermodynamic values calculated from
ﬁtting the binding isotherms are given in Table 1. However, attempts
to explain binding isotherms of Phd-1–3 binding to zwitterionic
membranes, POPC:Cholesterol (7:3) with surface partition equilibrium
model using Gouy–Chapman equations were unsuccessful. With this
model, no suitable binding constant was found which could describe
the experimental data in the entire concentration range (data not
shown).
3.2. Fluorescence polarization measurements
DPH is a rod-like molecule and partitions into the hydrophobic
core of the lipid bilayer [51]. TMA-DPH is oriented in the membrane
bilayer with its positive charge localized at the lipid–water interface
[51–53]. Fluorescence polarization of TMA-DPH and DPH in POPE:
POPG (7:3) and POPC:Cholesterol (7:3) membranes as a function
of increasing concentration of peptides is shown in Figs. 6(A–C)
and 7(A–C). Increase in ﬂuorescence polarization is observed with
TMA-DPH compared to DPH polarization. The increase is more signif-
icant for POPE:POPG (7:3) membranes.Fig. 6. Fluorescence polarization of TMA-DPH and DPH in POPE:POPG (7:3) LUVs as a
function of increasing concentration of peptides Phd-1–3. (■) TMA-DPH (●) DPH.
The concentration of lipid was 90 μM. The excitation wavelength used was 365 nm,
and emission was monitored at 425 nm. Measurements were carried out at room tem-
perature. Data points shown are the average of results from eight independent mea-
surements with SD of 0.005. (A) Phd-1, (B) Phd-2 and (C) Phd-3.
Fig. 7. Fluorescence polarization of TMA-DPH and DPH in POPC:Cholesterol (7:3) LUVs
as a function of increasing concentration of peptides Phd-1–3. (■) TMA-DPH (●) DPH.
The concentration of lipid was 180 μM. The excitation wavelength used was 365 nm,
and emission was monitored at 425 nm. Measurements were carried out at room tem-
perature. Data points shown are the average of results from eight independent mea-
surements with SD of 0.005. (A) Phd-1, (B) Phd-2 and (C) Phd-3.3.3. Membrane permeabilization measurements
The ability of the peptides to permeabilize POPE:POPG (7:3) mem-
branes, was investigated by monitoring the dissipation of diffusion
potential created by valinomycin (Fig. 8). The experiments were
carried out in the absence of salt, since the antibacterial activity of
Phd-1–3 was inhibited by high salt concentrations. All peptides
permeabilized POPE:POPG (7:3) lipid vesicles. Phd-3 permeabilizes
more effectively compared to Phd-1 and Phd-2. The maximum per-
cent ﬂuorescence recovery of Phd-3 is at a lipid–peptide ratio of
10:1 whereas for Phd-1 and Phd-2 the ratios are 3:1 and 2.5:1 respec-
tively. Clearly the peptides do not permeabilize lipid vesicles as
effectively as linear amphiphatic antibacterial peptides [46,54].
4. Discussion
Peptides Phd-1–3, spanning the cationic C-terminal region of HBD-
1–3, show antibacterial as well as antifungal activity with signiﬁcantly
lower hemolytic activities [18,22]. Lipid vesicles, mimicking bacterial
inner cytoplasmic membrane and eukaryotic membranes, are often
used to determine nature of peptide–membrane interactions to
correlate with their activities [31,36,37]. While these studies indicate
how speciﬁcity towards only bacteria and not eukaryotic cells such
Fig. 8. Maximal dissipation of diffusion potential in POPE:POPG (7:3) LUVs induced by
peptides. The peptides were added to 10 μM LUVs in 5 mM HEPES buffer pH 7.4 pree-
quilibratedwith the ﬂuorescent dye diS-C3-(5) and valinomycin. Fluorescence recovery
was measured after peptides were mixed with the vesicles. Key: (▲) Phd-1, (●) Phd-2
and (■) Phd-3.
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speciﬁcity towards Gram-negative or Gram-positive bacteria. ITC pro-
vides quantitative thermodynamic description for peptide adsorption
to and penetration into negatively charged and zwitterionic lipid
membranes [32,34,35,37,45,46]. In this study, the lipid membrane
partitioning of C-terminal analogs Phd-1–3 into LUVs composed of
POPE:POPG (7:3), POPC:Cholesterol (7:3) and POPC by ITC have
been investigated.
The calorimetric traces for all the three peptides Phd-1–3 binding
to POPE:POPG (7:3) vesicles at both 25 °C and 37 °C showed
complex titration proﬁles with two distinct regions of heat changes.
Such biphasic titrations proﬁles are reported for membrane
permeabilizing antibacterial peptides such as magainin and PGLa,
which have been attributed to pore formation [35,36]. Phd-1 showed
a signiﬁcantly different titration proﬁle compared to Phd-2, Phd-3 at
25 °C. However, at 37 °C, calorimetric traces for all the three peptides
are similar and differ from binding to POPC:Cholesterol (7:3) vesicles.
These proﬁles indicate that peptide–lipid interactions depend on tem-
perature and lipid composition. The shape of the binding isotherms
calculated from titration proﬁles is very similar to those reported
for other antimicrobial peptides like indolicidin, magainin and nisin
Z [34,35,37,45]. They exhibit a sharp change in the slope suggesting
a high co-operativity for the binding process [34]. The binding iso-
therms were analyzed by surface partition equilibrium model as
described for other cationic antibacterial peptides [34–37,46]. From
this data, it is evident that peptide surface concentration CM is much
higher than the equilibrium concentration of free peptide Cf, reﬂecting
strong electrostatic interaction between the membrane with its nega-
tive surface potential and the positively charged peptide. The derived
value of the apparent surface partition coefﬁcient K is low, which
reﬂects the contribution of exclusively less hydrophobic and other
non-electrostatic energies to binding process. Phd-1–3 binding
enthalpies ((ΔH~−1.3 to −2.8 kcal/mol) are less exothermic and
signiﬁcantly lower surface partition coefﬁcient K values compared
with other linear antimicrobial peptides such as PGLa (ΔH~−11 to
−15 kcal/mol) [36], magainin 2 amide M2a (ΔH=−17.0±1 kcal/
mol) [35] and indolicidin (ΔH=−5.6 kcal/mol) [34]. It has been
reported that coil to α-helix transition of peptide at the membrane
surface is associated with ΔH~−0.7 to −1.1 kcal/mol per residue
[55,56]. However, a large range of variation exists for enthalpy
of the coil to β-sheet formation. For example, the ΔHβ value for
model peptide (KIGAKI)3 is −0.23 kcal/mol per residue [56] and for
AcWL5 ΔHβ is −1.3 kcal/mol per residue [57]. The thermodynamic
values ΔH and K of Phd-1–3 indicate that they do not undergo
conformational changes upon binding or pore formation during their
interaction with membranes. Similar results were obtained from CD
data that showed no secondary structural variations between the
spectra recorded in aqueous buffer and in SDS micelles [18].Fluorescence polarization data clearly indicate that the peptides
interact with the negatively charged membrane surface of lipid vesi-
cles. The increase in ﬂuorescence polarization of TMA-DPH with
increasing concentration of peptide indicates that peptide interacts
with interfacial region of negatively charged membranes. This could
lead to membrane permeabilization of POPE:POPG (7:3) vesicles
which is evident from monitoring the dissipation of diffusion poten-
tial set up by valinomycin in the absence of salt [23,50,58].
Association of peptides with POPC:Cholesterol (7:3) vesicles are
relatively weak, which is reﬂected in lower enthalpy values of peptide
binding to POPC:Cholesterol (7:3) membranes. It is not possible to
evaluate ΔG and TΔS as the data of binding isotherms did not ﬁt
with Gouy–Chapman approach. The superﬁcial association of pep-
tides with POPC:Cholesterol (7:3) vesicles correlated with surface
pressure measurements of Phd-1–3 penetration into monolayers
composed of zwitterionic lipids [40]. Although a slight increase in
polarization and negative ΔH values indicate binding with POPC:
Cholesterol vesicles, this perturbation is not sufﬁcient to cause lysis
of red blood cells [22].
The overall hydrophobicity (ΔG kcal mol−1), was computed for
HBD-3 and analogs in an effort to rationalize their antibacterial activ-
ity and cytotoxicity [21], based on the scale proposed by White and
Wimley [59]. The ΔG values computed reﬂect peptide transfer from
the POPC bilayer interface to water. In a recent report, this scale
was also used to compute the average hydrophobicity of HBD-2 and
3, while studying their interactions with model bacterial and eukary-
otic membranes using synchrotron small-angle X-ray scattering [60].
The study indicated that HBD-2 and HBD-3 interacted weakly with
membranes rich in 1,2-dioleoyl-sn-glycero-3-phosphocholine and
the existence of distinct types of membrane curvature deformations
due to cationic arginine and lysine residues in lipid vesicles composed
of 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodium salt)/1,2-dio-
leoyl-sn-glycero-3-phosphoethanolamine [60]. Similarly, our ITC data
(shown in Fig. S1) does not indicate contribution of overall hydropho-
bicity to peptide interaction with POPC vesicles. Hence, we have not
computed overall hydrophobicity for Phd-1–3.
In an earlier paper, we have proposed that the amino-terminal
segments in both HBD-1 and 2 could contribute to speciﬁc antibacter-
ial activity towards Gram-negative bacteria [18]. Antibacterial activi-
ties of chimeric HBD-1/HBD-3 [61] and HBD-2/HBD-3 [62] have been
investigated with a view to address differences in their antimicrobial
spectrum and salt sensitivity. These studies have indicated signiﬁ-
cance of structure for antibacterial activity and identiﬁed different
domains or segments in HBD-1–3 that are critical for speciﬁc
antibacterial activity and salt sensitivity. The net positive charges
have been correlated with their observed antibacterial activity. The
results obtained from Phd-1–3 and extensive studies on chimeric
HBD-1–3 [61,62] suggest that electrostatic interactions between the
peptides and membrane components of bacteria are crucial for
antibacterial activity. Structural and charge requirements that impart
speciﬁc activity against Gram-negative or Gram-positive bacteria are
not yet apparent. The observation that HBD-2 interacts with glycosa-
mino glycans [63] and HBD-3 inhibits cell wall synthesis in staphylo-
cocci [64] indicates that the mechanism of killing by HBDs may not
involve only permeabilization of the lipid bilayer.
The results presented in this paper indicate that binding of Phd-1–3,
C-terminal analogs of HBD-1–3 to lipid membranes can be described
in terms of a surface partition equilibrium model for charged
membranes. The peptides show a signiﬁcant afﬁnity for negatively
charged membranes compared to zwitterionic membranes because of
electrostatic interactions. This explains their greater antimicrobial
activity compared to hemolytic activity. The electrostatic forces are
described by the Gouy–Chapman theory. The ΔG and TΔS values
indicate favorable interaction with negatively charged vesicles. The
low enthalpy and binding/partition coefﬁcient K values indicate no
conformational changes or pore formation during interaction with
1393V. Krishnakumari, R. Nagaraj / Biochimica et Biophysica Acta 1818 (2012) 1386–1394membranes. Thermodynamic analysis of peptides binding to speciﬁc
lipid composition reveals that peptide–lipid interactions are important
for their biological activities. The peptides permeabilize model
membranes less effectively compared to linear antibacterial peptides.
We propose that peptide adsorption on to the membrane head group
region causes membrane destabilization which in turn affects the
efﬁcient functioning of the cytoplasmic membrane proteins that could
lead to bacterial cell death.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbamem.2012.02.016.
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